Research & Literature

Calciphylaxis: risk factors, diagnosis, and treatment.

Nigwekar SU, Kroshinsky D, Nazarian RM, et al.

American journal of kidney diseases : the official journal of the National Kidney Foundation 2015; (66(1)):133-46.

A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation.

Wolf M, Weir MR, Kopyt N, et al.

Transplantation 2016; (100(1)):184-93 doi:10.1097/TP.0000000000000823.

Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis.

Sprague SM, Bellorin-Font E, Jorgetti V, et al.

American journal of kidney diseases : the official journal of the National Kidney Foundation 2016; (67(4)):559-66.

Pleiotropic effects of vitamin D in chronic kidney disease.

Liu WC, Wu CC, Hung YM, et al.

Clinica chimica acta; international journal of clinical chemistry 2016; (453()):1-12.

Changing bone patterns with progression of chronic kidney disease.

Drüeke TB, Massy ZA

Kidney international 2016; (89(2)):289-302.

We Use Too Much Vitamin D in Hemodialysis Patients.

Reilly RF

Seminars in dialysis 2016; (29(4)):320-2 doi:10.1111/sdi.12499.

Recent Changes in Chronic Kidney Disease-Mineral and Bone Disorders and Associated Fractures After Kidney Transplantation.

Perrin P, Kiener C, Javier RM, et al.

Transplantation 2017; (101(8)):1897-1905 doi:10.1097/TP.0000000000001449.

The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.

Habbous S, Przech S, Acedillo R, et al.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2017; (32(1)):111-125 doi:10.1093/ndt/gfw312.

Mineral metabolism and cardiovascular disease in CKD.

Fujii H, Joki N

Clinical and experimental nephrology 2017; (21(Suppl 1)):53-63 doi:10.1007/s10157-016-1363-8.

Risk factors and clinical course of hungry bone syndrome after total parathyroidectomy in dialysis patients with secondary hyperparathyroidism.

Ho LY, Wong PN, Sin HK, et al.

BMC nephrology 2017; (18(1)):12 doi:10.1186/s12882-016-0421-5.

Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA.

Sekercioglu N, Angeliki Veroniki A, Thabane L, et al.

PloS one 2017; (12(3)):e0171028 doi:10.1371/journal.pone.0171028.

Parathyroid hormone targets in chronic kidney disease and managing severe hyperparathyroidism.

Hawley CM, Holt SG

Nephrology (Carlton, Vic.) 2017; (22 Suppl 2()):47-50 doi:10.1111/nep.13029.

Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters.

Ketteler M, Block GA, Evenepoel P, et al.

Kidney international 2017; (92(1)):26-36 doi:10.1016/j.kint.2017.04.006.

Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes.

Pereira L, Meng C, Marques D, Frazão JM

Clinical kidney journal 2018; (11(1)):80-88 doi:10.1093/ckj/sfx125.

Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update.

Ketteler M, Block GA, Evenepoel P, et al.

Annals of internal medicine 2018; (168(6)):422-430 doi:10.7326/M17-2640.

Parathyroidectomy in the Management of Secondary Hyperparathyroidism.

Lau WL, Obi Y, Kalantar-Zadeh K

Clinical journal of the American Society of Nephrology : CJASN 2018; (13(6)):952-961 doi:10.2215/CJN.10390917.

Uremic Cardiomyopathy: A New Piece in the Chronic Kidney Disease-Mineral and Bone Disorder Puzzle.

de Albuquerque Suassuna PG, Sanders-Pinheiro H, de Paula RB

Frontiers in medicine 2018; (5()):206 doi:10.3389/fmed.2018.00206.

Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).

Ruospo M, Palmer SC, Natale P, et al.

The Cochrane database of systematic reviews 2018; (8()):CD006023 doi:10.1002/14651858.CD006023.pub3.

CKD, arterial calcification, atherosclerosis and bone health: Inter-relationships and controversies.

Reiss AB, Miyawaki N, Moon J, et al.

Atherosclerosis 2018; (278()):49-59 doi:10.1016/j.atherosclerosis.2018.08.046.

Sixty-Two-Year-Old Male Suffering From Uremic Leontiasis Ossea Caused by Severe Secondary Hyperparathyroidism.

Purrunsing Y, Zhang J, Cui Y, et al.

JBMR plus 2018; (2(4)):240-245 doi:10.1002/jbm4.10038.

Secondary hyperparathyroidism among Nigerians with chronic kidney disease.

Gimba ZM, Abene EE, Agbaji OOO, Agaba EI

African health sciences 2018; (18(2)):446-457 doi:10.4314/ahs.v18i2.30.

Bone mineral density, bone turnover markers, and incident fractures in de novo kidney transplant recipients.

Evenepoel P, Claes K, Meijers B, et al.

Kidney international 2019; (95(6)):1461-1470 doi:10.1016/j.kint.2018.12.024.

Changes in Bone Histomorphometry after Kidney Transplantation.

Keronen S, Martola L, Finne P, et al.

Clinical journal of the American Society of Nephrology : CJASN 2019; (14(6)):894-903 doi:10.2215/CJN.09950818.

Bone metabolism markers and hungry bone syndrome after parathyroidectomy in dialysis patients with secondary hyperparathyroidism.

Ge Y, Yang G, Wang N, et al.

International urology and nephrology 2019; (51(8)):1443-1449 doi:10.1007/s11255-019-02217-y.

Subtotal parathyroidectomy versus total parathyroidectomy with autotransplantation for secondary hyperparathyroidism: an updated systematic review and meta-analysis.

Yuan Q, Liao Y, Zhou R, et al.

Langenbeck's archives of surgery 2019; (404(6)):669-679 doi:10.1007/s00423-019-01809-7.

Parathyroidectomy as a Cure for Calciphylaxis in a Non-Dialysis Chronic Kidney Disease Patient?

Nasr R, Ghazanfar H

The American journal of case reports 2019; (20()):1170-1174 doi:10.12659/AJCR.917105.

The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism.

Bucharles SGE, Barreto FC, Riella MC

Jornal brasileiro de nefrologia 2019; (41(3)):336-344 doi:10.1590/2175-8239-JBN-2018-0219.

Cinacalcet plus vitamin D versus vitamin D alone for the treatment of secondary hyperparathyroidism in patients undergoing dialysis: a meta-analysis of randomized controlled trials.

Xu J, Yang Y, Ma L, et al.

International urology and nephrology 2019; (51(11)):2027-2036 doi:10.1007/s11255-019-02271-6.

Parathyroid Hormone Measurement in Chronic Kidney Disease: From Basics to Clinical Implications.

Kritmetapak K, Pongchaiyakul C

International journal of nephrology 2019; (2019()):5496710 doi:10.1155/2019/5496710.

Bone alkaline phosphatase: An important biomarker in chronic kidney disease - mineral and bone disorder.

Nizet A, Cavalier E, Stenvinkel P, et al.

Clinica chimica acta; international journal of clinical chemistry 2020; (501()):198-206 doi:10.1016/j.cca.2019.11.012.

Fatal Hypocalcaemia Due to Hungry Bone Syndrome with Secondary Refractory HyperParathyroidism After Parathyroidectomy: A Case Report.

Radu CP, Daniealopol V, Santini A, et al.

Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures) 2019; (5(4)):140-144 doi:10.2478/jccm-2019-0021.

Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Current Perspectives.

Waziri B, Duarte R, Naicker S

International journal of nephrology and renovascular disease 2019; (12()):263-276 doi:10.2147/IJNRD.S191156.

Hyperphosphatemia and Chronic Kidney Disease: A Major Daily Concern Both in Adults and in Children.

Bacchetta J, Bernardor J, Garnier C, et al.

Calcified tissue international 2021; (108(1)):116-127 doi:10.1007/s00223-020-00665-8.

Hungry bone syndrome after parathyroidectomy in end-stage renal disease patients: review of an alkaline phosphatase-based treatment protocol.

Wong J, Fu WH, Lim ELA, et al.

International urology and nephrology 2020; (52(3)):557-564 doi:10.1007/s11255-020-02387-0.

Current Understanding of Mineral and Bone Disorders of Chronic Kidney Disease and the Scientific Grounds on the Use of Exogenous Parathyroid Hormone in Its Management.

Pazianas M, Miller PD

Journal of bone metabolism 2020; (27(1)):1-13 doi:10.11005/jbm.2020.27.1.1.

Parathyroid Hormone: A Uremic Toxin.

Duque EJ, Elias RM, Moysés RMA

Toxins 2020; (12(3)) doi:10.3390/toxins12030189.

Intraoperative 99mTc-MIBI-Guided Parathyroidectomy Improves Curative Effect of Parathyroidectomy, Bone Metabolism, and Bone Mineral Density.

Chen J, Feng J, Zhou Q, et al.

The American surgeon 2021; (87(3)):463-472 doi:10.1177/0003134820951467.

Parathyroidectomy for patients with secondary hyperparathyroidism in a changing landscape for the management of end-stage renal disease.

van der Plas W, Kruijff S, Sidhu SB, et al.

Surgery 2021; (169(2)):275-281 doi:10.1016/j.surg.2020.08.014.

Brown tumor complicating end-stage kidney disease.

Wiederkehr M

Clinical nephrology. Case studies 2020; (8()):72-79 doi:10.5414/CNCS110195.

18F-Fluorocholine PET/CT, Tc-99m-MIBI and TC-99m-MDP SPECT/CT in Tertiary Hyperparathyroidism with Renal Osteodystrophy.

Ferrari C, Lavelli V, Santo G, et al.

Diagnostics (Basel, Switzerland) 2020; (10(10)) doi:10.3390/diagnostics10100851.

Surgical Management of Secondary Hyperparathyroidism.

Steinl GK, Kuo JH

Kidney international reports 2021; (6(2)):254-264 doi:10.1016/j.ekir.2020.11.023.

The Use of Imaging Techniques in Chronic Kidney Disease-Mineral and Bone Disorders (CKD-MBD)-A Systematic Review.

Pimentel A, Bover J, Elder G, et al.

Diagnostics (Basel, Switzerland) 2021; (11(5)) doi:10.3390/diagnostics11050772.

Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial.

Ogata H, Fukagawa M, Hirakata H, et al.

JAMA 2021; (325(19)):1946-1954 doi:10.1001/jama.2021.4807.

Independent effects of secondary hyperparathyroidism and hyperphosphataemia on chronic kidney disease progression and cardiovascular events: an analysis from the NEFRONA cohort.

Bozic M, Diaz-Tocados JM, Bermudez-Lopez M, et al.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2022; (37(4)):663-672 doi:10.1093/ndt/gfab184.

Where are we now? Emerging opportunities and challenges in the management of secondary hyperparathyroidism in patients with non-dialysis chronic kidney disease.

Ketteler M, Ambühl P

Journal of nephrology 2021; (34(5)):1405-1418 doi:10.1007/s40620-021-01082-2.

Prevalence and risk factors for tertiary hyperparathyroidism in kidney transplant recipients.

Sutton W, Chen X, Patel P, et al.

Surgery 2022; (171(1)):69-76 doi:10.1016/j.surg.2021.03.067.

Patterns of renal osteodystrophy 1 year after kidney transplantation.

Jørgensen HS, Behets G, Bammens B, et al.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2021; (36(11)):2130-2139 doi:10.1093/ndt/gfab239.

Impact of nutritional vitamin D supplementation on parathyroid hormone and 25-hydroxyvitamin D levels in non-dialysis chronic kidney disease: a meta-analysis.

Bover J, Gunnarsson J, Csomor P, et al.

Clinical kidney journal 2021; (14(10)):2177-2186 doi:10.1093/ckj/sfab035.

Natural History of Bone Disease following Kidney Transplantation.

Jørgensen HS, Behets G, Bammens B, et al.

Journal of the American Society of Nephrology : JASN 2022; (33(3)):638-652 doi:10.1681/ASN.2021081081.

Chronic Kidney Disease-Mineral Bone Disease Biomarkers in Kidney Transplant Patients.

Hasparyk UG, Vigil FMB, Bartolomei VS, et al.

Current medicinal chemistry 2022; (29(31)):5230-5253 doi:10.2174/0929867329666220318105856.

Calcium homeostasis and hyperparathyroidism: Nephrologic and endocrinologic points of view.

Lemoine S, Figueres L, Bacchetta J, et al.

Annales d'endocrinologie 2022; (83(4)):237-243 doi:10.1016/j.ando.2022.05.003.

A roadmap to parathyroidectomy for kidney transplant candidates.

Cianciolo G, Tondolo F, Barbuto S, et al.

Clinical kidney journal 2022; (15(8)):1459-1474 doi:10.1093/ckj/sfac050.

Treatment of secondary hyperparathyroidism in non-dialysis CKD: an appraisal 2022s.

Ketteler M, Bover J, Mazzaferro S

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2023; (38(6)):1397-1404 doi:10.1093/ndt/gfac236.

Hyperparathyroidism at 1 year after kidney transplantation is associated with graft loss.

Crepeau P, Chen X, Udyavar R, et al.

Surgery 2023; (173(1)):138-145 doi:10.1016/j.surg.2022.07.031.

Mechanistic insights into CKD-MBD-related vascular calcification and its clinical implications.

Kaur R, Singh R

Life sciences 2022; (311(Pt B)):121148 doi:10.1016/j.lfs.2022.121148.

[Diagnosis and treatment of osteoporosis in patients with chronic kidney disease : Joint guidelines of the Austrian Society for Bone and Mineral Research (ÖGKM), the Austrian Society of Physical and Rehabilitation Medicine (ÖGPMR) and the Austrian Society of Nephrology (ÖGN)].

Cejka D, Wakolbinger-Habel R, Zitt E, et al.

Wiener medizinische Wochenschrift (1946) 2023; (173(13-14)):299-318 doi:10.1007/s10354-022-00989-0.

Predictive value of characteristics of resected parathyroid glands for persistent secondary hyperparathyroidism during parathyroidectomy.

Huang Y, Wang J, Zeng M, et al.

BMC surgery 2023; (23(1)):36 doi:10.1186/s12893-023-01936-5.

Comparing subtotal parathyroidectomy and total parathyroidectomy with autotransplantation in renal transplant recipients.

Black KA, Galata G, Schulte KM, Hubbard JG

Gland surgery 2023; (12(8)):1060-1066 doi:10.21037/gs-23-54.

Current and Emerging Markers and Tools Used in the Diagnosis and Management of Chronic Kidney Disease-Mineral and Bone Disorder in Non-Dialysis Adult Patients.

Fusaro M, Pereira L, Bover J

Journal of clinical medicine 2023; (12(19)) doi:10.3390/jcm12196306.

Calcimimetics treatment strategy for serum calcium and phosphate management in patients with secondary hyperparathyroidism undergoing dialysis: A systematic review and meta-analysis of randomized studies.

Nakai K, Kono K, Yamada S, et al.

Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 2024; (28(4)):557-571 doi:10.1111/1744-9987.14125.

The Effects of Parathyroidectomy vs Medical Treatments for Secondary Hyperparathyroidism in Patients Undergoing Dialysis: A Meta-Analysis.

Song Z, Wu C, Wang R, et al.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2024; (30(6)):569-576 doi:10.1016/j.eprac.2024.04.002.

Improved Clinical Outcomes Associated With Hungry Bone Syndrome Following Parathyroidectomy in Dialysis Patients.

Silarat P, Saeseow S, Pathumarak A, et al.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2024; (30(11)):1079-1088 doi:10.1016/j.eprac.2024.08.004.

The Bone-Vascular Axis: A Key Player in Chronic Kidney Disease Associated Vascular Calcification.

Shen Y, Yu C

Kidney diseases (Basel, Switzerland) 2024; (10(6)):545-557 doi:10.1159/000541280.

Bone Health ECHO Case Report: High Bone Mass in a Patient with Chronic Kidney Disease.

Belaya Z, Przhiyalkovskaya E, Mamedova E, et al.

Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 2025; (28(1)):101554 doi:10.1016/j.jocd.2024.101554.

Chronic kidney disease-mineral and bone disorder: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Ketteler M, Evenepoel P, Holden RM, et al.

Kidney international 2025; (107(3)):405-423 doi:10.1016/j.kint.2024.11.013.

Recurrent Inflammatory State due to Severe Periarticular Calcifications in a Patient on Hemodialysis: A Case Report.

Timsans J, Vilpakka M, Lusila N, Kauppi M

Clinical case reports 2025; (13(2)):e70205 doi:10.1002/ccr3.70205.

Calciphylaxis Following Parathyroidectomy in Chronic Kidney Disease Patients-Case Report and Literature Review.

Akad N, Bilha SC, Apetrii M, et al.

Biomedicines 2025; (13(3)) doi:10.3390/biomedicines13030715.

Interventions to Reduce the Risk of Hypocalcemia After Parathyroidectomy for People With Advanced Chronic Kidney Disease: A Systematic Review.

Landsberg A, Brockman NK, Sevinc E, et al.

Canadian journal of kidney health and disease 2025; (12()):20543581251358144 doi:10.1177/20543581251358144.

Hungry Bone Syndrome After Parathyroidectomy for Secondary Hyperparathyroidism: Pathogenesis and Contemporary Clinical Considerations.

Coman A, Tarta C, Marian M, et al.

Journal of clinical medicine 2025; (14(19)) doi:10.3390/jcm14197104.

Vitamin D and Vitamin D Analogues in Hemodialysis Patients: A Review of the Literature.

Kantartzi K, Roumeliotis S, Polychronidis C, et al.

International journal of molecular sciences 2025; (26(23)) doi:10.3390/ijms262311550.

Comparison of parathormone lowering effects of paricalcitol and calcitriol in hemodialysis patients.

Murt A

World journal of nephrology 2025; (14(4)):110817 doi:10.5527/wjn.v14.i4.110817.

Incidence, risk factors and survival outcomes of post-transplant tertiary hyperparathyroidism in kidney recipients.

Hanson S, Menendez Lorenzo J, Chukwu CA, et al.

World journal of transplantation 2026; (16(1)):103656 doi:10.5500/wjt.v16.i1.103656.

Bilateral Olecranon and Left Lesser Trochanter Avulsion Fractures in Renal Osteodystrophy: A Rare Case Report and Comprehensive Review.

Papineni VRK, Botchu R, Iyengar KP, et al.

Acta medica Lituanica 2025; (32(2)):313-321 doi:10.15388/Amed.2025.32.2.1.

Surgery for kidney-related hyperparathyroidism: A review.

Kasmirski JA, Swaminathan N, Roy R, et al.

American journal of surgery 2026; (254()):116854 doi:10.1016/j.amjsurg.2026.116854.

Postparathyroidectomy calciphylaxis in a patient with primary hyperparathyroidism: a rare complication.

Karki A, Alomari L, Halliday J, et al.

JCEM case reports 2026; (4(3)):luag021 doi:10.1210/jcemcr/luag021.

Combination of Biomarkers and Novel Diagnostic Tools in the Management of Osteoporosis in Chronic Kidney Disease: An Update.

Mollica MV, Cianciolo G, Santoro C, et al.

Journal of clinical medicine 2026; (15(12)) doi:10.3390/jcm15124712.